Novaliq GmbH appoints Friedrich von Bohlen, PHD, as chairman and Gerald Cagle, PHD, as new member of Novaliq´s supervisory board

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that Friedrich von Bohlen, PhD, has been appointed Chairman of the company’s Supervisory Board and that Jerry Cagle, PhD, has joined the Board as Member. Dr. von Bohlen has been active…